SHIFT AI NewsroomWegovy tablet approved in the UK: what the new needle-free route meansApproved medicine news and practical contextWhen the clinic goes quiet, Shift stays onCompare treatment routes and honest availability

GOVERNED TREATMENT COMPARISON

Compare weight-loss treatments without pretending one answer fits everyone

This centre compares authorised routes and their practical differences. It does not diagnose, prescribe or decide suitability. Evidence records control the facts; a qualified prescriber controls the individual medicine decision.

Compare the five hero medicines interactively

OpenLive medicine comparison, prices and supply statusStartAnswer the short questions first

The live workspace lets you place any two hero medicines side by side after reading the full specification. It keeps stock honest and does not make a prescribing decision.

CompareRoute, frequency, evidence, access, routine and common effects.
Do not inferA trial average is not an individual forecast.
FreshnessMedicine status and dynamic facts are dated and source-controlled.
Clinical decisionSuitability remains with an appropriately qualified prescriber.

Mounjaro versus Wegovy

Mounjaro is weekly tirzepatide; Wegovy injection is weekly semaglutide. They target overlapping but not identical pathways and use different dose schedules. Head-to-head and separate trial evidence should be reported with population, duration and dose context.

The practical comparison includes response, side effects, dose route, availability, total service cost and whether the surrounding food, movement and follow-up plan is realistic.

Wegovy pill versus Foundayo

Both are daily GLP-1 tablets. Wegovy contains semaglutide and requires an overnight fast plus a wait before food or drink. Foundayo contains orforglipron and has greater flexibility around meals and water.

Separate trials do not create a direct winner. Routine, tolerability, medical history, expected benefit, cost and availability all require context.

Tablets versus injections

Tablets remove needles and refrigeration but require daily adherence; the Wegovy pill also creates a structured fasting routine. Weekly injections reduce dosing frequency but require storage, injection technique and sharps disposal.

Preference matters because a treatment that fits real life may be easier to use consistently. Preference cannot override safety or prescribing suitability.

Medication versus surgery

Medicines and bariatric procedures have different eligibility, evidence, reversibility, follow-up and risk profiles. Surgery is not a 'failure' and medicine is not 'cheating'. Both require informed decisions and long-term support.

People considering surgery need a specialist pathway, provider checks and a clear aftercare plan.

How this comparison is governed

Every medicine record must store its evidence source, UK authorisation status, evidence-review date and affected claims. If a dynamic fact cannot be verified, it should be withdrawn rather than guessed.

The interactive comparison workspace lets users choose two hero medicines and compare format, starting route, BMI context, evidence, downsides, live HQ price and supply. It remains decision support—not a recommendation or suitability result.

Frequently asked questions

Which weight-loss treatment is best?

There is no universal best treatment. Suitability depends on health, evidence, risks, route, routine, access and an individual assessment by an appropriately qualified professional.

Can separate trial percentages be compared directly?

Not reliably without context. Trials may use different populations, doses, durations and methods, so headline percentages should not be treated as a guaranteed league table.

Does this comparison prescribe or recommend treatment?

No. It provides general decision support. A qualified prescriber or specialist service remains responsible for an individual treatment decision.

Useful next steps

OpenCompare the five hero medicinesOpenMounjaro hubOpenWegovy hubOpenFoundayo hubOpenTreatment finder

Sources you can inspect

Sources support general information, not an individual suitability decision. External organisations remain responsible for their own content.

Who wrote this?

Matt O’Brien owns the research, writing and plain-English interpretation. Matt lost around 4½ stone over about eleven months through changes to eating, movement and prescribed weight-loss treatment after a clinical assessment. This is his personal experience, not a promise of results. He is not a clinician or prescriber. Read Matt’s full story.

Read Matt’s profile and the Shift research process →